Praziquantel therapy for Schistosoma manson infection in preschool-aged children

Optimization of praziquantel therapy for Schistosoma mansoni infection in preschool-aged children in Ethiopia: PrazOpt

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202008871179105

Enrollment

218

Registered

2020-08-07

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schistosomiasis

Interventions

Praziquantel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Written informed consent by parents/guardian - Age greater than or equal to 48 months and less than or equal to 84 months - Submission of 2 stool samples at baseline assessment

Exclusion criteria

Exclusion criteria: - Presence of any severe medical problem - Recent anthelminthic treatment - Use of other drugs within 5 half-lives of enrolment - History of hypersensitivity to praziquantel - Patients with ocular cysticercosis - Participation in other studies.

Design outcomes

Primary

Measure	Time frame
cure rate	—

Secondary

Measure	Time frame
- Egg reduction rate - Safety and tolerability (adverse events) - Estimates of pharmacokinetic parameters (AUC, Cmax, Tmax, t1/2, Tlag) - Correlates of curative outcome	—

Countries

Ethiopia

Contacts

Public ContactAbebaw Fekadu Wassie

Head of CDT Africa of Addis Ababa University

abebaw.fekadu@aau.edu.et+251912894975

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026